MedTrace Logo

Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

NCT03253926 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-07-26

Study results available
· View outcomes & findings →

Summary

In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.

Conditions

  • Cannabis Use

Interventions

DRUG

Lorcaserin

Lorcaserin 10mg BID

DRUG

Placebo

Placebo capsule BID

DRUG

Marijuana

Smoked marijuana cigarette

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • New York State Psychiatric Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-05
Primary Completion
2021-05-31
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03253926 on ClinicalTrials.gov